Analysed MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ) News Sources
European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading
18-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading
22-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
26-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week
29-05-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
01-06-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
02-06-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading
03-06-2026
yahoo.com
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
08-06-2026
yahoo.com
What is the current price of MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ)?
The current price of MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ) is $0.305.
MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ) absolute price change since previous trading day?
The absolute price change of MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ) since the previous trading day is $-0.0068.
MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ) percentage price change since previous trading day?
The percentage price change of MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ) since the previous trading day is -2.1809%.
What is the most recent average sentiment score for MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ)?
The most recent average sentiment score for MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ) is 18 out of 100.
What is the most recent average sentiment for MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ)?
The most recent sentiment for MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ) is .
SEC-8K** Filing Available For MEREO BIOPHARMA GROUP PL-ADR (MREO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.